Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 90 days matching "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"

Clinical trialUNITERAREMay 5

New Recruiting Trial: Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Novartis is testing a drug called asciminib in children who have a type of blood cancer called chronic myeloid leukemia (CML) that has a specific genetic change called the Philadelphia chromosome. This is a Phase 2 trial, which means researchers are checking if the drug works well and is safe in this younger age group. The study is now accepting patients and is expected to start in May 2026.

WHY IT MATTERSThis trial is the first to test asciminib specifically in pediatric patients with Ph+ CML-CP, potentially offering a new treatment option for children who may have limited alternatives or resistance to current therapies.
→ You can act on thisChronic Myeloid Leukemia, Chronic PhasePhiladelphia chromosome-positive CML
Clinical trialUNITERAREMay 3

New Recruiting Trial: Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Researchers are testing a new combination of three drugs—bugitinib, venetoclax, and cytarabine—to treat acute myeloid leukemia (AML) that has come back or stopped responding to previous treatment. This is an early-stage study (Phase 2) that is now accepting patients. The goal is to see if this drug combination works better than current options for this serious blood cancer.

WHY IT MATTERSThis trial offers a new treatment option for patients with relapsed or refractory AML, a condition with limited effective therapies, and is actively recruiting participants now.
→ You can act on thisacute myeloid leukemiarelapsed acute myeloid leukemiarefractory acute myeloid leukemia
Clinical trialUNITERAREApr 5

New Recruiting Trial: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, and then puts them back into the body. This Phase 1 trial is for people with blood cancers like leukemia and lymphoma. The treatment is personalized—each patient's cells are customized based on their individual cancer's unique mutations.

WHY IT MATTERSThis trial offers patients with hematologic malignancies access to a cutting-edge personalized immunotherapy that targets their cancer's unique mutations, potentially offering a new treatment option for those who may have limited alternatives.
→ You can act on thisacute myeloid leukemiaacute lymphoblastic leukemiachronic myeloid leukemia
ResearchPUBMEDMar 26

[New ways in interdisciplinarity: internal medicine meets human genetics : When frequent conditions become rare and rare conditions become frequent].

Doctors are learning that common diseases are actually made up of many different rare subtypes when scientists look at their genetic makeup. By understanding the specific genetic changes in each person's disease, doctors can create targeted treatments that work better. This article uses chronic myeloid leukemia as an example—a treatment that targets one specific genetic change has turned a deadly disease into one people can live with for decades.

WHY IT MATTERSIf you have been diagnosed with a common cancer or disease, genetic testing may reveal you have a rare molecular subtype that qualifies you for a precision medicine treatment not available to patients with other genetic variations of the same disease.
💬 Ask your doctorchronic myeloid leukemiacancer

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases